or marketing any new Product, any such improperly undisclosed Product shall be deemed to be included in this definition.
“Product Agreement” means each agreement, license, document, instrument, interest (equity or otherwise) or the like under which one or more parties grants or receives any right, title or interest with respect to any Product Development and Commercialization Activities in respect of one or more Products specified therein or to exclude third parties from engaging in, or otherwise restricting any right, title or interest as to any Product Development and Commercialization Activities with respect thereto, including each contract or agreement with suppliers, manufacturers, pharmaceutical companies, distributors, clinical research organizations, hospitals, group purchasing organizations, wholesalers, pharmacies or any other Person related to any such entity.
“Product Authorizations” means any and all approvals, licenses, notifications, registrations or authorizations of any Governmental Authority for the testing, manufacture, development, distribution, use, storage, import, export, transport, promotion, marketing, sale or commercialization of a Product in any country or jurisdiction, including without limitation registration and listing, INDs, NDAs, ANDAs and similar applications.
“Product Development and Commercialization Activities” means, with respect to any Product, any combination of research, development, manufacture, import, use, sale, importation, storage, labeling, marketing, promotion, supply, distribution, testing, packaging, purchasing or other commercialization activities, receipt of payment in respect of any of the foregoing, or like activities the purpose of which is to develop or commercially exploit such Product.
“Pro Forma Basis” means, with respect to any Acquisition, such Acquisition shall be deemed to have occurred on and as of the first day of the most recently completed four (4) Fiscal Quarter period for which the Credit Parties have delivered financial statements to the Administrative Agent pursuant to Section 5.01(c) or Section 7.01 and, in connection with the foregoing, income statement items (whether positive or negative) attributable to the target of such Acquisition shall be included in the results of the Credit Parties and their Subsidiaries for such period.
“Public Company Costs” means costs incurred by Super Holdings and its Subsidiaries in connection with its reporting obligations under, or in connection with compliance with, applicable laws or applicable rules of any governmental, regulatory or self-regulatory body or stock exchange, this Agreement or any other agreement or instrument relating to Indebtedness of the Issuer or any Credit Party, including the provisions of the Securities Act, the Exchange Act or respective rules and regulations promulgated thereunder, in each case as applicable to companies with equity or debt securities held by the public, the rules of national securities exchange companies with listed equity or debt securities, directors’ compensation, fees, indemnities and expense reimbursement, costs relating to investor relations, shareholder meetings and reports to shareholders or debtholders, listing fees and all executive, legal and professional fees related to the foregoing and for any equivalence thereof.
“Public Issuer Materials” has the meaning set forth in Section 7.02.
“Purchase and Sale Agreement” means the purchase and sale agreement, dated as of June 24, 2021, by and among Acella Holdings, LLC, a Delaware limited liability company, RVL Pharmaceuticals plc, a public limited company incorporated under the laws of Ireland, the Persons listed on Schedule I-A thereto, and Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelōsségü Társaság, a company limited by quotas organized under the Laws of Hungary, and solely for purposes of providing the guaranty pursuant to Section 12.16 thereto, Alora Pharmaceuticals, LLC, a Delaware limited liability company.